By Kelly Cloonan
FibroGen has terminated its previous exclusive license and option agreement with HiFiBiO and agreed to license certain intellectual property to the company.
Under the terms of the new agreement, FibroGen has licensed its anti-CCR8 and anti-Gal-9 intellectual property to HiFiBiO, the biopharmaceutical company said Friday.
If HiFiBiO sublicenses either asset, FibroGen is eligible to receive a mid single-digit to low double-digit share of HiFiBiO's license revenues and a low double-digit share of commercial royalties, the company said.
If HiFiBiO commercializes either asset, FibroGen could receive single digit royalties based on worldwide net sales.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
June 13, 2025 16:47 ET (20:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。